Literature DB >> 17475219

Transgenic MMP-2 expression induces latent cardiac mitochondrial dysfunction.

Hui-Zhong Zhou1, Xiaokui Ma, Mary O Gray, Bo-qing Zhu, Anita P Nguyen, Anthony J Baker, Ursula Simonis, Gary Cecchini, David H Lovett, Joel S Karliner.   

Abstract

Matrix metalloproteinases (MMPs) are central to the development and progression of dysfunctional ventricular remodeling after tissue injury. We studied 6 month old heterozygous mice with cardiac-specific transgenic expression of active MMP-2 (MMP-2 Tg). MMP-2 Tg hearts showed no substantial gross alteration of cardiac phenotype compared to age-matched wild-type littermates. However, buffer perfused MMP-2 Tg hearts subjected to 30 min of global ischemia followed by 30 min of reperfusion had a larger infarct size and greater depression in contractile performance compared to wild-type hearts. Importantly, cardioprotection mediated by ischemic preconditioning (IPC) was completely abolished in MMP-2 Tg hearts, as shown by abnormalities in mitochondrial ultrastructure and impaired respiration, increased lipid peroxidation, cell necrosis and persistently reduced recovery of contractile performance during post-ischemic reperfusion. We conclude that MMP-2 functions not only as a proteolytic enzyme but also as a previously unrecognized active negative regulator of mitochondrial function during superimposed oxidative stress.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17475219      PMCID: PMC3423089          DOI: 10.1016/j.bbrc.2007.04.094

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  29 in total

1.  Intracellular action of matrix metalloproteinase-2 accounts for acute myocardial ischemia and reperfusion injury.

Authors:  Wenjie Wang; Costas J Schulze; Wilma L Suarez-Pinzon; Jason R B Dyck; Grzegorz Sawicki; Richard Schulz
Journal:  Circulation       Date:  2002-09-17       Impact factor: 29.690

2.  A functional activating protein 1 (AP-1) site regulates matrix metalloproteinase 2 (MMP-2) transcription by cardiac cells through interactions with JunB-Fra1 and JunB-FosB heterodimers.

Authors:  Marina R Bergman; Sunfa Cheng; Norman Honbo; Lucia Piacentini; Joel S Karliner; David H Lovett
Journal:  Biochem J       Date:  2003-02-01       Impact factor: 3.857

3.  Cardiac matrix metalloproteinase-2 expression independently induces marked ventricular remodeling and systolic dysfunction.

Authors:  Marina R Bergman; John R Teerlink; Rajeev Mahimkar; Luyi Li; Bo-Qing Zhu; Anita Nguyen; Sia Dahi; Joel S Karliner; David H Lovett
Journal:  Am J Physiol Heart Circ Physiol       Date:  2006-12-08       Impact factor: 4.733

4.  Matrix metalloproteinase-2 contributes to ischemia-reperfusion injury in the heart.

Authors:  P Y Cheung; G Sawicki; M Wozniak; W Wang; M W Radomski; R Schulz
Journal:  Circulation       Date:  2000-04-18       Impact factor: 29.690

5.  Left ventricular remodeling and ventricular arrhythmias after myocardial infarction.

Authors:  Martin St John Sutton; Douglas Lee; Jean Lucien Rouleau; Steven Goldman; Ted Plappert; Eugene Braunwald; Marc A Pfeffer
Journal:  Circulation       Date:  2003-05-05       Impact factor: 29.690

6.  Increased circulating matrix metalloproteinase-2 in patients with hypertrophic cardiomyopathy with systolic dysfunction.

Authors:  Yoshihiro Noji; Masami Shimizu; Hidekazu Ino; Toshinori Higashikata; Masato Yamaguchi; Atsushi Nohara; Takahiro Horita; Kuniyoshi Shimizu; Yuji Ito; Takeshi Matsuda; Masanobu Namura; Hiroshi Mabuchi
Journal:  Circ J       Date:  2004-04       Impact factor: 2.993

7.  Matrix metalloproteinase-2 (MMP-2) is present in the nucleus of cardiac myocytes and is capable of cleaving poly (ADP-ribose) polymerase (PARP) in vitro.

Authors:  Jennifer A Kwan; Costas J Schulze; Wenjie Wang; Hernando Leon; Meltem Sariahmetoglu; Miranda Sung; Jolanta Sawicka; David E Sims; Grzegorz Sawicki; Richard Schulz
Journal:  FASEB J       Date:  2004-02-06       Impact factor: 5.191

8.  Preservation of base-line hemodynamic function and loss of inducible cardioprotection in adult mice lacking protein kinase C epsilon.

Authors:  Mary O Gray; Hui-Zhong Zhou; Ingeborg Schafhalter-Zoppoth; Peili Zhu; Daria Mochly-Rosen; Robert O Messing
Journal:  J Biol Chem       Date:  2003-11-04       Impact factor: 5.157

9.  Circulating matrix metalloproteinase-2 is elevated in patients with congestive heart failure.

Authors:  Taketoshi Yamazaki; Jong-Dae Lee; Hiromasa Shimizu; Hiroyasu Uzui; Takanori Ueda
Journal:  Eur J Heart Fail       Date:  2004-01       Impact factor: 15.534

10.  Duration of ischaemia determines matrix metalloproteinase-2 activation in the reperfused rabbit heart.

Authors:  Ananth M Prasan; Hugh C K McCarron; Melanie Y White; Susan V McLennan; Adrian S Tchen; Brett D Hambly; Richmond W Jeremy
Journal:  Proteomics       Date:  2002-09       Impact factor: 3.984

View more
  28 in total

1.  Transgenic expression of matrix metalloproteinase-2 induces coronary artery ectasia.

Authors:  Sia Dahi; Joel S Karliner; Rajabrata Sarkar; David H Lovett
Journal:  Int J Exp Pathol       Date:  2010-10-29       Impact factor: 1.925

2.  Association of matrix metalloproteinase-2 gene promoter polymorphism with myocardial infarction susceptibility in a Mexican population.

Authors:  Ivan Delgado-Enciso; Nelida A Gonzalez-Hernandez; Luz M Baltazar-Rodriguez; Rebeca O Millan-Guerrero; Oscar Newton-Sanchez; Alfonso Bayardo-Noriega; Alfonso Aleman-Mireles; Irma G Enriquez-Maldonado; Ma J Anaya-Carrillo; Augusto Rojas-Martinez; Rocio Ortiz-Lopez
Journal:  J Genet       Date:  2009-08       Impact factor: 1.166

3.  In vitro transcriptomic prediction of hepatotoxicity for early drug discovery.

Authors:  Feng Cheng; Dan Theodorescu; Ira G Schulman; Jae K Lee
Journal:  J Theor Biol       Date:  2011-08-27       Impact factor: 2.691

Review 4.  Mitochondrial mitophagic mechanisms of myocardial matrix metabolism and remodelling.

Authors:  Thomas P Vacek; Jonathan C Vacek; Suresh C Tyagi
Journal:  Arch Physiol Biochem       Date:  2011-12-19       Impact factor: 4.076

5.  MicroRNA expression in response to murine myocardial infarction: miR-21 regulates fibroblast metalloprotease-2 via phosphatase and tensin homologue.

Authors:  Sashwati Roy; Savita Khanna; Syed-Rehan A Hussain; Sabyasachi Biswas; Ali Azad; Cameron Rink; Surya Gnyawali; Shani Shilo; Gerard J Nuovo; Chandan K Sen
Journal:  Cardiovasc Res       Date:  2009-01-15       Impact factor: 10.787

6.  Mitochondrial matrix metalloproteinase activation decreases myocyte contractility in hyperhomocysteinemia.

Authors:  Karni S Moshal; Srinivas M Tipparaju; Thomas P Vacek; Munish Kumar; Mahavir Singh; Iluiana E Frank; Phani K Patibandla; Neetu Tyagi; Jayesh Rai; Naira Metreveli; Walter E Rodriguez; Michael T Tseng; Suresh C Tyagi
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-06-20       Impact factor: 4.733

7.  Apoptotic effect of mtrix metalloproteinases 9 in the development of diabetic retinopathy.

Authors:  Yu Chen; Wen Wang; Fen Liu; Luosheng Tang; Renhong Tang; Wenjie Li
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

8.  Restoration of contractility in hyperhomocysteinemia by cardiac-specific deletion of NMDA-R1.

Authors:  Karni S Moshal; Munish Kumar; Neetu Tyagi; Paras K Mishra; Naira Metreveli; Walter E Rodriguez; Suresh C Tyagi
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-01-30       Impact factor: 4.733

9.  Matrix metalloproteinase-2 in the development of diabetic retinopathy and mitochondrial dysfunction.

Authors:  Ghulam Mohammad; Renu A Kowluru
Journal:  Lab Invest       Date:  2010-05-17       Impact factor: 5.662

10.  Immunosuppression With FTY720 Reverses Cardiac Dysfunction in Hypomorphic ApoE Mice Deficient in SR-BI Expression That Survive Myocardial Infarction Caused by Coronary Atherosclerosis.

Authors:  Fu Sang Luk; Roy Y Kim; Kang Li; Daniel Ching; David K Wong; Sunil K Joshi; Isabella Imhof; Norman Honbo; Holly Hoover; Bo-Qing Zhu; David H Lovett; Joel S Karliner; Robert L Raffai
Journal:  J Cardiovasc Pharmacol       Date:  2016-01       Impact factor: 3.105

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.